- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.
- Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.
- Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney. In 2009, approximately 49,000 people were diagnosed with renal cell carcinoma and 11,000 people died from the disease.
Tuesday, October 20, 2009
Votrient (pazopanib) approved for advanced kidney cancer
Votrient (pazopanib) has been approved by the FDA for the treatment of advanced kidney cancer. Votrient is made by GlaxoSmithKline (GSK).